Vizirgianakis Stavros G.

SEC source: 0001559834-26-000001 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,838,845

F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on August 15, 2027, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 1,843,491 shares issuable upon settlement of DSUs granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.

SEC source: 0001493152-26-028771 · ownership.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,196,191

F1 · kind: The restricted stock units vest as follows: (i) 150,000 restricted stock units vest immediately on June 11, 2026 (the "Grant Date"); (ii) 150,000 restricted stock units will commence vesting on the first anniversary of the Grant Date and will vest ratably over the twelve (12) month period beginning on such date; and (iii) 150,000 restricted stock units will commence vesting on the second anniversary of the Grant Date and will vest ratably over the twelve (12) month period beginning on such date, in each case subject to the Reporting Person's continued service through each applicable vesting date and the terms and conditions of the applicable award agreement.

SEC source: 0001559834-25-000006 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,515,570

F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 1,520,215 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

SEC source: 0001641172-25-011477 · ownership.xml · derivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,000

Underlying: Common Stock · 128,000 shares

Expires 2035-05-15

F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a twelve (12) month period and shall become fully vested and fully exercisable on the first anniversary of the date of grant.

SEC source: 0001493152-25-002767 · ownership.xml · derivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-01-15

F1 · derivative.exercise_date: Issued pursuant to the Issuer's Director Compensation Program, as amended, which provides for the issuance of a stock option to non-employee directors with an exercise price equal to the closing price of the Issuer's common stock on its principal exchange on the second trading day following the Issuer's release of its preliminary 2024 revenue. The option vests ratably over a 12-month period and becomes fully vested and exercisable on the first anniversary of the date of grant.

SEC source: 0001235802-24-000071 · primary_doc.xml · nonDerivative · entry 2

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,961,773

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2025, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.

F2 · balance_after: Includes 966,418 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

SEC source: 0001235802-24-000071 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,456,368

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2025, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.

F2 · balance_after: Includes 966,418 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

SEC source: 0001493152-24-031316 · ownership.xml · derivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2034-08-08

F1 · derivative.exercise_date: Issued pursuant to the Issuer's Director Compensation Program as set forth in the Issuer's definitive proxy statement filed with the U.S. Securities and Exchange Commission on June 25, 2024, which provides for the issuance of a stock option to non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. The option vests ratably over a 12-month period and becomes fully vested and exercisable on the first anniversary of the date of grant.

SEC source: 0001235802-23-000094 · primary_doc.xml · derivative · entry 2

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,345

Underlying: Common Stock · 42,345 shares

Expires 2033-08-15

F3 · derivative.exercise_date: This option vests on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-23-000094 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,213,125

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 217,770 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-22-000122 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,995,355

F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Second Amended and Restated 2018 Equity Incentive Plan, (as amended from time to time, the "2018 Equity Plan"), and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 215,415 shares to be issued upon vesting pursuant to restricted stock unit awards granted under the 2018 Equity Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-22-000113 · primary_doc.xml · derivative · entry 2

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 566,214

Underlying: Common Stock · 566,214 shares

Expires 2027-08-25

F3 · security: This warrant was issued in a second and final tranche of a private placement pursuant to the securities purchase agreement by and among Xtant Medical Holdings, Inc. and several accredited investors.

F4 · balance_after: This total does not include a warrant to purchase 878,770 shares of common stock issued on August 25, 2022. Such warrant was immediately exercisable as of the date of issuance and previously reported by the Reporting Person on a Form 4 filed with the Securities and Exchange Commission on August 26, 2022.

SEC source: 0001235802-22-000113 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,850,716

F1 · shares: These shares were issued in a second and final tranche of a private placement pursuant to a securities purchase agreement by and among Xtant Medical Holdings, Inc. and several accredited investors.

F2 · balance_after: Includes 70,776 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

SEC source: 0001235802-22-000107 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,585,855

F1 · shares: These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 70,776 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date.

F3 · balance_after: Includes 3,515,079 shares issued in connection with the first closing of the private placement (the "Private Placement") pursuant to the securities purchase agreement by and among Xtant Medical Holdings, Inc. and several accredited investors. Does not include 2,264,861 shares to be issued in connection with the second closing of the Private Placement, which will be issued subject to the satisfaction of certain closing conditions.

SEC source: 0000899243-22-023647 · doc4.xml · derivative · entry 3

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,648

Underlying: Class A Common Stock · 16,648 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date.

F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date.

SEC source: 0000899243-22-023647 · doc4.xml · derivative · entry 2

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,930

Underlying: Class A Common Stock · 965 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

F2 · derivative.exercise_date: The remaining RSUs shall vest and become exercisable in two approximately equal installments on June 16, 2023 and June 16, 2024, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date.

F2 · derivative.expiration_date: The remaining RSUs shall vest and become exercisable in two approximately equal installments on June 16, 2023 and June 16, 2024, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date.

SEC source: 0000899243-22-023647 · doc4.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,781,888

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-042368 · doc4.xml · derivative · entry 8

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,895

Underlying: Class A Common Stock · 2,895 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock

F5 · derivative.exercise_date: The restricted stock units shall vest and become exercisable in three equal installments, with the first installment vesting and becoming exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant (such earlier date, the "Installment Vesting Date") and the second and third installments vesting and becoming exercisable on the first and second anniversaries of the Installment Vesting Date, respectively, in each case subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.

F5 · derivative.expiration_date: The restricted stock units shall vest and become exercisable in three equal installments, with the first installment vesting and becoming exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant (such earlier date, the "Installment Vesting Date") and the second and third installments vesting and becoming exercisable on the first and second anniversaries of the Installment Vesting Date, respectively, in each case subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.

SEC source: 0000899243-21-042368 · doc4.xml · derivative · entry 7

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 261,794

Underlying: Class A Common Stock · 261,794 shares

Expires 2030-06-29

F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each option to purchase Misonix Inc. ("Misonix") common stock (a "Misonix Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into an option to acquire the number of shares of Class A common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares of Misonix common stock subject to such Misonix Option immediately prior to the First Effective Time (as defined in the Merger Agreement);

F3 · price: (continued from footnote 2) by (B) the Option Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of shares of the Issuer's Class A common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Misonix Option by the Option Exchange Ratio, rounded up to the nearest whole cent.

F1 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0000899243-21-042368 · doc4.xml · derivative · entry 6

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,001

Underlying: Class A Common Stock · 89,001 shares

Expires 2030-06-29

F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each option to purchase Misonix Inc. ("Misonix") common stock (a "Misonix Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into an option to acquire the number of shares of Class A common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares of Misonix common stock subject to such Misonix Option immediately prior to the First Effective Time (as defined in the Merger Agreement);

F3 · price: (continued from footnote 2) by (B) the Option Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of shares of the Issuer's Class A common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Misonix Option by the Option Exchange Ratio, rounded up to the nearest whole cent.

F1 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0000899243-21-042368 · doc4.xml · derivative · entry 5

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 347,323

Underlying: Class A Common Stock · 347,323 shares

Expires 2030-05-13

F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each option to purchase Misonix Inc. ("Misonix") common stock (a "Misonix Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into an option to acquire the number of shares of Class A common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares of Misonix common stock subject to such Misonix Option immediately prior to the First Effective Time (as defined in the Merger Agreement);

F3 · price: (continued from footnote 2) by (B) the Option Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of shares of the Issuer's Class A common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Misonix Option by the Option Exchange Ratio, rounded up to the nearest whole cent.

F1 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0000899243-21-042368 · doc4.xml · derivative · entry 4

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,905

Underlying: Class A Common Stock · 34,905 shares

Expires 2029-11-22

F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each option to purchase Misonix Inc. ("Misonix") common stock (a "Misonix Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into an option to acquire the number of shares of Class A common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares of Misonix common stock subject to such Misonix Option immediately prior to the First Effective Time (as defined in the Merger Agreement);

F3 · price: (continued from footnote 2) by (B) the Option Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of shares of the Issuer's Class A common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Misonix Option by the Option Exchange Ratio, rounded up to the nearest whole cent.

F1 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0000899243-21-042368 · doc4.xml · derivative · entry 3

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,634

Underlying: Class A Common Stock · 19,634 shares

Expires 2026-02-04

F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each option to purchase Misonix Inc. ("Misonix") common stock (a "Misonix Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into an option to acquire the number of shares of Class A common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares of Misonix common stock subject to such Misonix Option immediately prior to the First Effective Time (as defined in the Merger Agreement);

F3 · price: (continued from footnote 2) by (B) the Option Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of shares of the Issuer's Class A common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Misonix Option by the Option Exchange Ratio, rounded up to the nearest whole cent.

F1 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0000899243-21-042368 · doc4.xml · derivative · entry 2

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,544

Underlying: Class A Common Stock · 6,544 shares

Expires 2023-12-03

F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each option to purchase Misonix Inc. ("Misonix") common stock (a "Misonix Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into an option to acquire the number of shares of Class A common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares of Misonix common stock subject to such Misonix Option immediately prior to the First Effective Time (as defined in the Merger Agreement);

F3 · price: (continued from footnote 2) by (B) the Option Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of shares of the Issuer's Class A common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Misonix Option by the Option Exchange Ratio, rounded up to the nearest whole cent.

F1 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0000899243-21-042368 · doc4.xml · derivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,179

Underlying: Class A Common Stock · 26,179 shares

Expires 2025-02-03

F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each option to purchase Misonix Inc. ("Misonix") common stock (a "Misonix Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into an option to acquire the number of shares of Class A common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares of Misonix common stock subject to such Misonix Option immediately prior to the First Effective Time (as defined in the Merger Agreement);

F3 · price: (continued from footnote 2) by (B) the Option Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of shares of the Issuer's Class A common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Misonix Option by the Option Exchange Ratio, rounded up to the nearest whole cent.

F1 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001493152-21-030853 · ownership.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers").

F2 · shares: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F3 · shares: Includes 450,000 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement).

F1 · price: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers").

F2 · price: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F3 · price: Includes 450,000 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement).

SEC source: 0000899243-22-015851 · doc4.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,780,923

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each share of Misonix Inc. ("Misonix") common stock (a "Misonix Option") that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of the Company's Class A Common Stock, $0.001 par value per share ("Bioventus Shares"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

SEC source: 0001493152-21-016049 · ownership.xml · derivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2031-06-29

F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2017 Equity Incentive Plan. Stock Options vest in 48 equal monthly installments on the anniversary of the grant date, June 30, 2021.

SEC source: 0001493152-20-012459 · ownership.xml · derivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,995

Underlying: Common Stock · 50,995 shares

Expires 2030-06-29

F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2017 Equity Incentive Plan. Stock Options vest in 48 equal monthly installments on the anniversary of the grant date, June 30, 2020.

SEC source: 0001213900-20-013113 · ownership.xml · derivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,005

Underlying: Common Stock · 199,005 shares

Expires 2030-05-13

F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2017 Equity Incentive Plan. Stock Options vest in 48 equal monthly installments on the anniversary of the grant date, May 14, 2020.

SEC source: 0001213900-20-006143 · ownership.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,649,078

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.62 to $9.93. The reporting person undertakes to provide to Misonix, any security holder of Misonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

SEC source: 0001213900-19-024784 · ownership.xml · derivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2029-11-22

F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2017 Equity Incentive Plan. Stock Options vest in four equal annual installments on the anniversary of the grant date, November 22, 2019.

SEC source: 0001615774-17-005318 · s107569_form4.xml · derivative · entry 4

Vizirgianakis Stavros G. · CIK 0001559834 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 3,750 shares

Expires 2026-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001615774-17-005318 · s107569_form4.xml · derivative · entry 3

Vizirgianakis Stavros G. · CIK 0001559834 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,750 shares

Expires 2023-05-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001615774-17-005318 · s107569_form4.xml · nonDerivative · entry 2

Vizirgianakis Stavros G. · CIK 0001559834 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,641,078

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001615774-17-005318 · s107569_form4.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,637,328

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001615774-16-009021 · s104987_form4.xml · derivative · entry 4

Vizirgianakis Stavros G. · CIK 0001559834 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,750

Underlying: Common Stock · 11,250 shares

Expires 2023-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001615774-16-009021 · s104987_form4.xml · derivative · entry 3

Vizirgianakis Stavros G. · CIK 0001559834 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,750

Underlying: Common Stock · 11,250 shares

Expires 2023-05-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001615774-16-009021 · s104987_form4.xml · nonDerivative · entry 2

Vizirgianakis Stavros G. · CIK 0001559834 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,633,578

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001615774-16-009021 · s104987_form4.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,622,328

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001615774-16-008964 · s104966_form4.xml · nonDerivative · entry 3

Vizirgianakis Stavros G. · CIK 0001559834 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,611,078

F3 · shares: Grant of performance restricted stock vesting based on revenue and stock price thresholds.

SEC source: 0001615774-16-008964 · s104966_form4.xml · nonDerivative · entry 2

Vizirgianakis Stavros G. · CIK 0001559834 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,478,078

F2 · shares: Grant of performance restricted stock vesting based on revenue and stock price thresholds.

SEC source: 0001615774-16-008964 · s104966_form4.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,345,078

F1 · shares: Grant of restricted stock vesting in five equal installments on 9/1/2017, 9/1/2018, 9/1/2019. 9/1/2020 and 9/1/2021.

SEC source: 0001615774-16-007752 · s104394_form4.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director · Interim CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,211,078